1
|
Moraska AR, Atherton PJ, Szydlo DW, Barton DL, Stella PJ, Rowland KM, Schaefer PL, Krook JE, Bearden J, Loprinzi CL. Gabapentin for the management of hot flashes in prostate cancer survivors: A longitudinal continuation study—NCCTG trial N00CB. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
2
|
Liu H, Sloan JA, Sargent DJ, Satele DV, Schaefer PL, Halyard MY, Grothey A, Garces YI, Brown PD, Buckner JC. Assessing simple measures of patient-reported (PR) fatigue for oncology clinical trials: A pooled analysis of 3,915 patients. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9563 Background: Fatigue is a prevalent and debilitating symptom reported by cancer patients (pts) which compromises a pt's quality of life (QOL). This study examined the relationship between PR fatigue and QOL as well as cancer-related symptoms (CRS) in 43 North Central Cancer Treatment Group and Mayo Clinic Cancer Center clinical trials. Methods: 3,915 pts from 43 oncology clinical trials provided baseline fatigue data on a single-item 0–100 point scale. Pts' QOL assessment included a single-item overall QOL and associated QOL domains measured by numerical analogues, the Profile of Mood States (POMS), and PR symptom assessment measures. Associations between fatigue and QOL domains were assessed by Spearman correlation coefficients. Wilcoxon rank sum test compared QOL scores between pts with clinically deficient fatigue(CDF, score ≤50) vs. no clinically deficient fatigue (nCDF, score>50). Changes from baseline in fatigue and QOL were compared by Wilcoxon rank sum test with a 20-point change defined as clinically meaningful. Results: 38% of pts reported CDF at baseline and 45% of pts reported CDF at last assessment. Fatigue was only moderately correlated at best with overall QOL, pain, POMS, social and physical function (Spearman rho's of .27,.40, .56, .38 and .38 respectively). Pts with CDF averaged over 10 points lower overall QOL, pain, POMS, social, and physical function (see table below, all p<.0001) as well as worsening CRS including sleepiness, nausea, headache, abnormal sweating, trouble sleeping, dry mouth, and sexual dysfunction (all p<.001). Pts with 20+ points worsening in fatigue declined in overall QOL, physical function, pain and POMS (all p<.0001). Conclusions: Patients with CDF suffer greater deficits in QOL and CRS. Patients report fatigue as distinctly different from overall QOL, pain, physical, social, mood status and CRS. Fatigue appears with a broad spectrum of CRS clusters. Routine measurement and management of fatigue could impact QOL and treatment-related symptoms. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- H. Liu
- Mayo Clinic, Rochester, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic, Scottsdale, AZ
| | - J. A. Sloan
- Mayo Clinic, Rochester, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic, Scottsdale, AZ
| | - D. J. Sargent
- Mayo Clinic, Rochester, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic, Scottsdale, AZ
| | - D. V. Satele
- Mayo Clinic, Rochester, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic, Scottsdale, AZ
| | - P. L. Schaefer
- Mayo Clinic, Rochester, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic, Scottsdale, AZ
| | - M. Y. Halyard
- Mayo Clinic, Rochester, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic, Scottsdale, AZ
| | - A. Grothey
- Mayo Clinic, Rochester, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic, Scottsdale, AZ
| | - Y. I. Garces
- Mayo Clinic, Rochester, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic, Scottsdale, AZ
| | - P. D. Brown
- Mayo Clinic, Rochester, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic, Scottsdale, AZ
| | - J. C. Buckner
- Mayo Clinic, Rochester, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic, Scottsdale, AZ
| |
Collapse
|
3
|
Sloan JA, Liu H, Sargent DJ, Satele D, Schaefer PL, Halyard MY, Grothey A, Garces YI, Brown PD, Loprinzi CL, Buckner JC. A patient-level pooled analysis of the prognostic significance of baseline fatigue for overall survival (OS) among 3,915 patients participating in 43 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9599 Background: We have previously identified overall a single-item measure for baseline quality of life (QOL) as a strong prognostic factor for survival (Tan, ASCO 2008), and that fatigue was an important component of patient QOL (Sloan, 2007). To explore whether patient-reported fatigue was supplemental or redundant to the prognostic information of overall QOL, we performed a patient-level pooled analysis of 43 NCCTG and MCCC oncology clinical trials of the effect of baseline fatigue on OS. Methods: 3,915 patients participating in 43 trials provided data at baseline for fatigue on a single-item 0–100 point scale. OS was tested for association with clinically deficient fatigue (CDF, score 0–50, n=1,497) vs not clinically deficient fatigue (nCDF, score 51–100, n=2,418). Cox proportional hazards models adjusted for the effects of overall QOL, performance score, race, disease site, age and gender. Results: Baseline fatigue was a strong predictor of OS for the entire patient cohort (CDF vs. nCDF: 31.5 mos vs >83.9 mos, p<0.0001). The effect sizes were consistent across different disease sites (GI, esophageal, head and neck, prostate, lung, breast and others). After controlling for covariates, including performance status and overall QOL, baseline fatigue remained a strong prognostic factor in multivariate models (CDF vs. nCDF: HR=1.23, p=0.02). Conclusions: Fatigue is a strong prognostic factor for OS independent of overall QOL and PS in a wide variety of oncology patient populations. Single-item measures of overall QOL and fatigue can help to identify vulnerable subpopulations among cancer patients. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. A. Sloan
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| | - H. Liu
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| | - D. J. Sargent
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| | - D. Satele
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| | - P. L. Schaefer
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| | - M. Y. Halyard
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| | - A. Grothey
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| | - Y. I. Garces
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| | - P. D. Brown
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| | - C. L. Loprinzi
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| | - J. C. Buckner
- Mayo Clinic, Rochester, MN; Toledo Clinic, Toledo, OH; Mayo Clinic Arizona, Scottsdale, AZ
| |
Collapse
|
4
|
Johnson BS, Dueck AC, Dakhil SR, Stella PJ, Nikcevich DA, Franco SX, Wender DB, Schaefer PL, Colon-Otero G, Diekmann BB, Perez EA. Tolerability of lapatinib given concurrently with paclitaxel and trastuzumab as part of adjuvant therapy in patients with resected HER2+ breast cancer: initial safety data from the Mayo Clinic cancer research consortium trial RC0639. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-2109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #2109
Background: Despite the impressive results of the recently released trastuzumab adjuvant therapy trials, 15% of patients with HER2 overexpressing or amplified breast cancer developed tumor relapse at 4 years. Lapatinib is a small molecule reversible TKI that inhibits both ErbB1 and ErbB2. The current study was developed to assess the cardiac safety and feasibility of adding lapatinib to paclitaxel and trastuzumab following as part of adjuvant therapy.
 Methods: A single-arm phase II study of doxorubicin (A, 60 mg/m2 day 1) and cyclophosphamide (C, 600 mg/m2 day 1) [q2w or q3w for 4 cycles]; followed by paclitaxel (P, 80 mg/m2 days 1, 8, 15), trastuzumab (T, 4 mg/kg loading dose then 2 mg/kg days 1, 8, 15), and lapatinib (L, 1000 mg days 1-21) [12 weeks]; followed by T (6 mg/kg day 1) and L (1000 mg days 1-21) [40 weeks] was conducted. The primary endpoint was the incidence of congestive heart failure. The current unplanned safety analysis was undertaken due to the observance of a high rate of G3/4 diarrhea.
 Results: From April 2007 to June 2008, 98 pts were enrolled and initiated study treatment. Median age was 51 (range 32-72). Among 83 pts with adverse event (AE) data available, 50 (60%) pts have experienced a G3/4 non-hematologic AE. During post-AC treatment, among 53 pts with AE data available, 31 (58.5%) patients have experienced a G3/4 non-hematologic AE with 24 (45%) patients reporting G3/4 diarrhea. Median cycle of onset of G3/4 diarrhea was cycle 5 (first cycle of PTL) with 16 (64%) cases first reported during cycle 5 and 5 (20%) cases first reported during cycle 6. Among 57, 46, 38, and 32 pts receiving treatment with PTL during cycles 5-8, 65%, 57%, 61%, and 72% of patients received the full L dose, respectively. 31 patients have ended active treatment with 10 due to patient refusal and 8 due to adverse events.
 Conclusions: Preliminary data suggest that L given concurrently with P and T at a dose of 1000 mg per day induces an unacceptable rate of moderate to severe diarrhea. Careful monitoring of diarrhea as well as L dose reduction and initiation of loperamide at first occurrence of diarrhea are recommended. The dose of L when given concurrently with P and T has been amended to 750 mg per day in the current study and safety data for the 1000 mg and 750 mg per day cohorts will be presented. Implications for the ongoing ALTTO study will also be presented.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2109.
Collapse
Affiliation(s)
| | | | | | - PJ Stella
- 4 Michigan Consortium, Ann Arbor, MI
| | | | | | - DB Wender
- 6 Siouxland Hem-Onc Assoc, Sioux City, IA
| | | | | | | | | |
Collapse
|
5
|
Liu H, Tan AD, Grothey A, Schaefer PL, Buckner JC, Loprinzi CL, Morton RF, Sloan JA. Comparing and validating simple measures of patient-reported peripheral neuropathy (PRPN) for NCCTG Clinical Trials: A pooled analysis of 2,440 patients (pts). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.9534] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
6
|
Mincey BA, Dentchev T, Sloan JA, Hines SL, Perez EA, Johnson DB, Schaefer PL, Liu H, Kahanic SP, Loprinzi CL. N03CC—a randomized, controlled, open-label trial of upfront vs. delayed zoledronic acid for prevention of bone loss in postmenopausal (PM) women with primary breast cancer (PBC) starting letrozole after tamoxifen. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.564] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Burger K, Atherton PJ, Schaefer PL, Halyard MY, Sloan JA. Compliance issues in completion of patient-reported outcomes in a series of NCCTG/Mayo clinical trials. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.17506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
TAN AD, Novotny PJ, Kaur JS, Buckner JC, Schaefer PL, Stella PJ, Kuebler JP, Sloan JA. A patient-level meta-analytic investigation of the prognostic significance of baseline quality of life (QOL) for overall survival (OS) among 3,704 patients participating in 24 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.9515] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Dakhil SR, Loprinzi CL. Does tetracycline prevent/palliate epidermal growth factor receptor (EGFR) inhibitor-induced rash? A phase III trial from the North Central Cancer Treatment Group (N03CB). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.lba9006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA9006 Purpose: Many patients who receive EGFR inhibitors develop an acneiform rash, and anecdotal reports suggest tetracycline is effective in treating it. To our knowledge, however, no rigorous trials have ever been published to substantiate this approach. This double- blinded, placebo-controlled trial was conducted to assess the role of tetracycline in preventing EGFR inhibitor-induced rash and/or reducing its severity. Methods: 61 patients were randomly assigned to tetracycline 500 mg orally twice a day×4 weeks versus an identical, similarly prescribed placebo. Eligibility criteria required all patients to have begun an EGFR inhibitor </= 7 days prior with no rash at study entry. Patients were to be followed for 8 weeks. Physician assessments of rash incidence, severity, and adverse events, occurred at 4 and 8 weeks. Patients completed a weekly rash diary, quality of life questionnaire (SKINDEX-16), and EGFR inhibitor compliance questionnaire. Thirty patients per group provides 90% power to detect a difference in rash incidence (the primary endpoint) of 40% between groups and of rejecting the null hypothesis of equal proportions with a type I error of 5% (2-sided). Results: Treatment arms were balanced on baseline characteristics, drop out rates, and rates of discontinuation of the EGFR inhibitor. Rash incidence was comparable across arms. Physicians reported that 16 tetracycline-treated patients (70%) and 22 placebo-exposed patients (76%) developed a rash (p=0.61). However, tetracycline appears to have lessened rash severity. By week 4, physician-reported grade 2 rash occurred in 17% of tetracycline-treated patients (n=4) and 55% of placebo- exposed patients (n=16); (p=0.04). Tetracycline-treated patients reported better scores on certain quality of life parameters (SKINDEX-16), such as skin burning or stinging, skin irritation, and being bothered by a persistence/recurrence of a skin condition. Adverse events were comparable across arms. Conclusion: Tetracycline did not prevent EGFR inhibitor-induced rashes. However, diminished rash severity and improved quality of life suggest this antibiotic merits further study. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Jatoi
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - K. Rowland
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - J. A. Sloan
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - H. M. Gross
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - P. A. Fishkin
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - S. P. Kahanic
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - P. J. Novotny
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - P. L. Schaefer
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - S. R. Dakhil
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| | - C. L. Loprinzi
- Mayo Clinic College of Medicine, Rochester, MN; Carle Cancer Center, Urbana, IL; Hematology & Oncology of Dayton, Inc., Dayton, OH; Oncology Hematology Associates, Peoria, IL; Siouxland Regional Cancer Center, Sioux City, IA; Mayo Clinic, Rochester, MN; Toledo Community Hospital Program (TCHOP), Toledo, OH; Wichita Community Clinical Oncology Program, Wichita, KS
| |
Collapse
|
10
|
Mandrekar SJ, Huschka MM, Schaefer PL, Jett JR, Adjei AA, Sloan JA. What is the value added of patient reported outcomes relative to physician rated symptom assessments? J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.8580] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8580 Background: This pooled analysis examined the relationship between single-item and multiple-item quality of life (QOL) measures and assessed the agreement between changes in QOL and patient-reported adverse events (AE). Methods: Data from six lung cancer clinical trials involving 358 patients were pooled. All trials incorporated the UNISCALE and one of three multiple-item assessments: the Functional Assessment for Cancer Therapy-Lung, the Lung Cancer Symptom Scale, or the Symptom Distress Scale. A clinically significant decline (CSD) in QOL was defined as a 10-point drop from baseline. A CSD in AE was defined as a change from ≤ grade 2 at baseline to ≥ grade 3 post-baseline. Spearman rank correlations and Bland-Altman approach were used to assess agreement. The Kaplan-Meier method was used to evaluate the time to the first occurrence of a severe (grade 3+) AE and first CSD in QOL. Results: Correlations between the UNISCALE and multi-item assessments were modest (rho=0.49–0.66). At least one 10-point decline in the UNISCALE and multi-item assessments were reported by 58% and 40% respectively. At least one severe AE was reported in 44% of patients post-baseline. The percent agreement between experiencing a severe AE and a CSD in QOL was 49% and 59% for UNISCALE and the multi-item tools. For individual AE, the percent agreement between a CSD in AE and a CSD in QOL ranged from 37% to 50% for UNISCALE and 44% to 69% for the multi-item tools. The median time to the first CSD in QOL for UNISCALE and multi-item tools was 67 and 142 days respectively. The median time to the first occurrence of a severe AE was 304 days. Conclusions: QOL and AE provide quantifiably different information. A 10-point decline in QOL occurs earlier than CTC AE reporting. Patient reported outcomes may be more sensitive in identifying clinically relevant problems than physician rated symptom assessments. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | | | | | - J. R. Jett
- Mayo Clinic, Rochester, MN; Toledo CCOP, Toledo, OH
| | - A. A. Adjei
- Mayo Clinic, Rochester, MN; Toledo CCOP, Toledo, OH
| | - J. A. Sloan
- Mayo Clinic, Rochester, MN; Toledo CCOP, Toledo, OH
| |
Collapse
|
11
|
Tan AD, Novotny PJ, Kaur JS, Buckner JC, Schaefer PL, Stella PJ, Sloan JA. Comparison of baseline quality of life between minority and non-minority patients participating in oncology clinical trials. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.8527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8527 Background: Minority patients (MP) suffer deficits in access to care and socioeconomic status. This study uses a patient-level pooled analysis to explore whether these deficits translate into quality of life (QOL) differences between MP and non-MP on clinical trials. Method: Baseline QOL scores were combined from 47 clinical trials (6,513 patients) conducted either at the Mayo Clinic Cancer Center or in the North Central Cancer Treatment Group. QOL scales used were the Uniscale, Linear Analogue Self Assessment (LASA), Symptom Distress Scale (SDS), Profile of Mood States (POMS) and Functional Assessment of Cancer Therapy - General (Fact-G). Fisher’s Exact tests and linear regression adjusted for age, site, and performance score. Survival data was compared using the method of Kaplan-Meier. Results: Eight percent (531) of patients self-reported as MP (0.45% American Indian/Alaskan Native, 0.7% Asian, 5% Black/African American, 1.5% Hispanic, 0.1% Native Hawaiian and 0.3% Other). MP had no meaningful deficits in overall QOL or the SDS and were slightly worse on FACT-G total score, physical, social/family, functional, and SDS nausea severity. MP among lung cancer patients reported greater nausea (58 vs 69) and sleep problems (34 vs 54), with neurological cancers reported worse emotional well-being (53 vs 74), and with GI tumors had lower social/family well-being (60 vs 67). Regression models confirmed these results. Median survival time was shorter for MP (198 vs 310 days, p=0.001) but was not significant after adjusting for disease severity. Conclusions: MP on these clinical trials did not report large QOL deficits at baseline relative to non-MP. MP did indicate small deficits in physical, social, and emotional subscales. MP experienced large tumor-specific deficits for a few QOL domains that might bear further attention. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. D. Tan
- Mayo Clinic, Rochester, MN; TCCOP, Toledo, OH; St. Joseph Mercy Health System, Ann Arbor, MI
| | - P. J. Novotny
- Mayo Clinic, Rochester, MN; TCCOP, Toledo, OH; St. Joseph Mercy Health System, Ann Arbor, MI
| | - J. S. Kaur
- Mayo Clinic, Rochester, MN; TCCOP, Toledo, OH; St. Joseph Mercy Health System, Ann Arbor, MI
| | - J. C. Buckner
- Mayo Clinic, Rochester, MN; TCCOP, Toledo, OH; St. Joseph Mercy Health System, Ann Arbor, MI
| | - P. L. Schaefer
- Mayo Clinic, Rochester, MN; TCCOP, Toledo, OH; St. Joseph Mercy Health System, Ann Arbor, MI
| | - P. J. Stella
- Mayo Clinic, Rochester, MN; TCCOP, Toledo, OH; St. Joseph Mercy Health System, Ann Arbor, MI
| | - J. A. Sloan
- Mayo Clinic, Rochester, MN; TCCOP, Toledo, OH; St. Joseph Mercy Health System, Ann Arbor, MI
| |
Collapse
|
12
|
McMillan DE, Schaefer PL, Sloan JA, Morgenthaler TI, Novotny PJ, Yang P, Huntington JL, Beardon JD, Mailliard JA, Loprinzi CL. A pooled analysis to estimate the prevalence of sleep complaints among cancer patients. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. E. McMillan
- Univ of Manitoba, Winnipeg, MB, Canada; Toledo Community Hospitals Oncology Program CCOP, Toledo, OH; Mayo Clinic, Rochester, MN; Spartan Regional Medcl Ctr, Spartanburg, SC; Missouri Valley Cancer Consortium, Omaha, NE
| | - P. L. Schaefer
- Univ of Manitoba, Winnipeg, MB, Canada; Toledo Community Hospitals Oncology Program CCOP, Toledo, OH; Mayo Clinic, Rochester, MN; Spartan Regional Medcl Ctr, Spartanburg, SC; Missouri Valley Cancer Consortium, Omaha, NE
| | - J. A. Sloan
- Univ of Manitoba, Winnipeg, MB, Canada; Toledo Community Hospitals Oncology Program CCOP, Toledo, OH; Mayo Clinic, Rochester, MN; Spartan Regional Medcl Ctr, Spartanburg, SC; Missouri Valley Cancer Consortium, Omaha, NE
| | - T. I. Morgenthaler
- Univ of Manitoba, Winnipeg, MB, Canada; Toledo Community Hospitals Oncology Program CCOP, Toledo, OH; Mayo Clinic, Rochester, MN; Spartan Regional Medcl Ctr, Spartanburg, SC; Missouri Valley Cancer Consortium, Omaha, NE
| | - P. J. Novotny
- Univ of Manitoba, Winnipeg, MB, Canada; Toledo Community Hospitals Oncology Program CCOP, Toledo, OH; Mayo Clinic, Rochester, MN; Spartan Regional Medcl Ctr, Spartanburg, SC; Missouri Valley Cancer Consortium, Omaha, NE
| | - P. Yang
- Univ of Manitoba, Winnipeg, MB, Canada; Toledo Community Hospitals Oncology Program CCOP, Toledo, OH; Mayo Clinic, Rochester, MN; Spartan Regional Medcl Ctr, Spartanburg, SC; Missouri Valley Cancer Consortium, Omaha, NE
| | - J. L. Huntington
- Univ of Manitoba, Winnipeg, MB, Canada; Toledo Community Hospitals Oncology Program CCOP, Toledo, OH; Mayo Clinic, Rochester, MN; Spartan Regional Medcl Ctr, Spartanburg, SC; Missouri Valley Cancer Consortium, Omaha, NE
| | - J. D. Beardon
- Univ of Manitoba, Winnipeg, MB, Canada; Toledo Community Hospitals Oncology Program CCOP, Toledo, OH; Mayo Clinic, Rochester, MN; Spartan Regional Medcl Ctr, Spartanburg, SC; Missouri Valley Cancer Consortium, Omaha, NE
| | - J. A. Mailliard
- Univ of Manitoba, Winnipeg, MB, Canada; Toledo Community Hospitals Oncology Program CCOP, Toledo, OH; Mayo Clinic, Rochester, MN; Spartan Regional Medcl Ctr, Spartanburg, SC; Missouri Valley Cancer Consortium, Omaha, NE
| | - C. L. Loprinzi
- Univ of Manitoba, Winnipeg, MB, Canada; Toledo Community Hospitals Oncology Program CCOP, Toledo, OH; Mayo Clinic, Rochester, MN; Spartan Regional Medcl Ctr, Spartanburg, SC; Missouri Valley Cancer Consortium, Omaha, NE
| |
Collapse
|
13
|
Steensma DP, Molina R, Sloan JA, Nikcevich DA, Schaefer PL, Rowland KM, Dentchev T, Tschetter LK, Novotny PJ, Loprinzi CL. A phase III randomized trial of two different dosing schedules of erythropoietin (EPO) in patients with cancer-associated anemia: North Central Cancer Treatment Group (NCCTG) Study N02C2. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8031] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. P. Steensma
- Mayo Clinic, Rochester, MN; Iowa Oncology Research Assn CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN; Toledo Community Hosp Oncology Program CCOP, Toledo, OH; Carle Cancer Ctr CCOP, Urbana, IL; Altru Health System, Grand Forks, ND; Sioux Community Cancer Consortium, Sioux Falls, SD
| | - R. Molina
- Mayo Clinic, Rochester, MN; Iowa Oncology Research Assn CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN; Toledo Community Hosp Oncology Program CCOP, Toledo, OH; Carle Cancer Ctr CCOP, Urbana, IL; Altru Health System, Grand Forks, ND; Sioux Community Cancer Consortium, Sioux Falls, SD
| | - J. A. Sloan
- Mayo Clinic, Rochester, MN; Iowa Oncology Research Assn CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN; Toledo Community Hosp Oncology Program CCOP, Toledo, OH; Carle Cancer Ctr CCOP, Urbana, IL; Altru Health System, Grand Forks, ND; Sioux Community Cancer Consortium, Sioux Falls, SD
| | - D. A. Nikcevich
- Mayo Clinic, Rochester, MN; Iowa Oncology Research Assn CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN; Toledo Community Hosp Oncology Program CCOP, Toledo, OH; Carle Cancer Ctr CCOP, Urbana, IL; Altru Health System, Grand Forks, ND; Sioux Community Cancer Consortium, Sioux Falls, SD
| | - P. L. Schaefer
- Mayo Clinic, Rochester, MN; Iowa Oncology Research Assn CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN; Toledo Community Hosp Oncology Program CCOP, Toledo, OH; Carle Cancer Ctr CCOP, Urbana, IL; Altru Health System, Grand Forks, ND; Sioux Community Cancer Consortium, Sioux Falls, SD
| | - K. M. Rowland
- Mayo Clinic, Rochester, MN; Iowa Oncology Research Assn CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN; Toledo Community Hosp Oncology Program CCOP, Toledo, OH; Carle Cancer Ctr CCOP, Urbana, IL; Altru Health System, Grand Forks, ND; Sioux Community Cancer Consortium, Sioux Falls, SD
| | - T. Dentchev
- Mayo Clinic, Rochester, MN; Iowa Oncology Research Assn CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN; Toledo Community Hosp Oncology Program CCOP, Toledo, OH; Carle Cancer Ctr CCOP, Urbana, IL; Altru Health System, Grand Forks, ND; Sioux Community Cancer Consortium, Sioux Falls, SD
| | - L. K. Tschetter
- Mayo Clinic, Rochester, MN; Iowa Oncology Research Assn CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN; Toledo Community Hosp Oncology Program CCOP, Toledo, OH; Carle Cancer Ctr CCOP, Urbana, IL; Altru Health System, Grand Forks, ND; Sioux Community Cancer Consortium, Sioux Falls, SD
| | - P. J. Novotny
- Mayo Clinic, Rochester, MN; Iowa Oncology Research Assn CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN; Toledo Community Hosp Oncology Program CCOP, Toledo, OH; Carle Cancer Ctr CCOP, Urbana, IL; Altru Health System, Grand Forks, ND; Sioux Community Cancer Consortium, Sioux Falls, SD
| | - C. L. Loprinzi
- Mayo Clinic, Rochester, MN; Iowa Oncology Research Assn CCOP, Des Moines, IA; Duluth CCOP, Duluth, MN; Toledo Community Hosp Oncology Program CCOP, Toledo, OH; Carle Cancer Ctr CCOP, Urbana, IL; Altru Health System, Grand Forks, ND; Sioux Community Cancer Consortium, Sioux Falls, SD
| |
Collapse
|
14
|
Sloan JA, Schaefer PL, Witzig TE, Novotny PJ, Silberstein PT, Beardon JD, Allred JB, Mailliard JA, Loprinzi CL. Relationships among quality of life and survival in anemic patients with advanced cancer undergoing chemotherapy. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. A. Sloan
- Mayo Clinic, Rochester, MN; Toledo Community Hospitals Oncology Program CCOP, Toledo, OH; Creighton Univ, Omaha, NE; Spartan Regional Medcl Ctr, Spartanburg, SC; Missouri Valley Cancer Consortium, Omaha, NE
| | - P. L. Schaefer
- Mayo Clinic, Rochester, MN; Toledo Community Hospitals Oncology Program CCOP, Toledo, OH; Creighton Univ, Omaha, NE; Spartan Regional Medcl Ctr, Spartanburg, SC; Missouri Valley Cancer Consortium, Omaha, NE
| | - T. E. Witzig
- Mayo Clinic, Rochester, MN; Toledo Community Hospitals Oncology Program CCOP, Toledo, OH; Creighton Univ, Omaha, NE; Spartan Regional Medcl Ctr, Spartanburg, SC; Missouri Valley Cancer Consortium, Omaha, NE
| | - P. J. Novotny
- Mayo Clinic, Rochester, MN; Toledo Community Hospitals Oncology Program CCOP, Toledo, OH; Creighton Univ, Omaha, NE; Spartan Regional Medcl Ctr, Spartanburg, SC; Missouri Valley Cancer Consortium, Omaha, NE
| | - P. T. Silberstein
- Mayo Clinic, Rochester, MN; Toledo Community Hospitals Oncology Program CCOP, Toledo, OH; Creighton Univ, Omaha, NE; Spartan Regional Medcl Ctr, Spartanburg, SC; Missouri Valley Cancer Consortium, Omaha, NE
| | - J. D. Beardon
- Mayo Clinic, Rochester, MN; Toledo Community Hospitals Oncology Program CCOP, Toledo, OH; Creighton Univ, Omaha, NE; Spartan Regional Medcl Ctr, Spartanburg, SC; Missouri Valley Cancer Consortium, Omaha, NE
| | - J. B. Allred
- Mayo Clinic, Rochester, MN; Toledo Community Hospitals Oncology Program CCOP, Toledo, OH; Creighton Univ, Omaha, NE; Spartan Regional Medcl Ctr, Spartanburg, SC; Missouri Valley Cancer Consortium, Omaha, NE
| | - J. A. Mailliard
- Mayo Clinic, Rochester, MN; Toledo Community Hospitals Oncology Program CCOP, Toledo, OH; Creighton Univ, Omaha, NE; Spartan Regional Medcl Ctr, Spartanburg, SC; Missouri Valley Cancer Consortium, Omaha, NE
| | - C. L. Loprinzi
- Mayo Clinic, Rochester, MN; Toledo Community Hospitals Oncology Program CCOP, Toledo, OH; Creighton Univ, Omaha, NE; Spartan Regional Medcl Ctr, Spartanburg, SC; Missouri Valley Cancer Consortium, Omaha, NE
| |
Collapse
|
15
|
Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, Dakhil SR, Levitt R, Novotny PJ, Loprinzi CL. Phase III clinical trial evaluating low-molecular weight heparin (LMWH) in patients with advanced cancer: A North Central Cancer Treatment Group study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8186] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. Sideras
- Mayo Clinic, Rochester, MN; Toldeo Community Hosp Oncology Program CCOP, Toledo, OH; Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Mayo Clinic, Scottsdale, AZ; Wichita Community Onology Program, Wichita, KS; Merticare Hosp CCOP, Fargo, ND
| | - P. L. Schaefer
- Mayo Clinic, Rochester, MN; Toldeo Community Hosp Oncology Program CCOP, Toledo, OH; Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Mayo Clinic, Scottsdale, AZ; Wichita Community Onology Program, Wichita, KS; Merticare Hosp CCOP, Fargo, ND
| | - S. H. Okuno
- Mayo Clinic, Rochester, MN; Toldeo Community Hosp Oncology Program CCOP, Toledo, OH; Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Mayo Clinic, Scottsdale, AZ; Wichita Community Onology Program, Wichita, KS; Merticare Hosp CCOP, Fargo, ND
| | - J. A. Sloan
- Mayo Clinic, Rochester, MN; Toldeo Community Hosp Oncology Program CCOP, Toledo, OH; Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Mayo Clinic, Scottsdale, AZ; Wichita Community Onology Program, Wichita, KS; Merticare Hosp CCOP, Fargo, ND
| | - L. Kutteh
- Mayo Clinic, Rochester, MN; Toldeo Community Hosp Oncology Program CCOP, Toledo, OH; Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Mayo Clinic, Scottsdale, AZ; Wichita Community Onology Program, Wichita, KS; Merticare Hosp CCOP, Fargo, ND
| | - T. R. Fitch
- Mayo Clinic, Rochester, MN; Toldeo Community Hosp Oncology Program CCOP, Toledo, OH; Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Mayo Clinic, Scottsdale, AZ; Wichita Community Onology Program, Wichita, KS; Merticare Hosp CCOP, Fargo, ND
| | - S. R. Dakhil
- Mayo Clinic, Rochester, MN; Toldeo Community Hosp Oncology Program CCOP, Toledo, OH; Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Mayo Clinic, Scottsdale, AZ; Wichita Community Onology Program, Wichita, KS; Merticare Hosp CCOP, Fargo, ND
| | - R. Levitt
- Mayo Clinic, Rochester, MN; Toldeo Community Hosp Oncology Program CCOP, Toledo, OH; Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Mayo Clinic, Scottsdale, AZ; Wichita Community Onology Program, Wichita, KS; Merticare Hosp CCOP, Fargo, ND
| | - P. J. Novotny
- Mayo Clinic, Rochester, MN; Toldeo Community Hosp Oncology Program CCOP, Toledo, OH; Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Mayo Clinic, Scottsdale, AZ; Wichita Community Onology Program, Wichita, KS; Merticare Hosp CCOP, Fargo, ND
| | - C. L. Loprinzi
- Mayo Clinic, Rochester, MN; Toldeo Community Hosp Oncology Program CCOP, Toledo, OH; Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA; Mayo Clinic, Scottsdale, AZ; Wichita Community Onology Program, Wichita, KS; Merticare Hosp CCOP, Fargo, ND
| |
Collapse
|
16
|
Buckner JC, Aldape KD, Ballman K, Scheithauer BW, Burger PC, Giannini C, Schaefer PL, Jenkins RB, James CD. Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.1508] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. C. Buckner
- Mayo Clinic College of Medicine, Rochester, MN; MD Anderson, Houston, TX; Johns Hopkins University School of Medicine, Baltimore, MD; Toledo Community CCOP, Toledo, OH
| | - K. D. Aldape
- Mayo Clinic College of Medicine, Rochester, MN; MD Anderson, Houston, TX; Johns Hopkins University School of Medicine, Baltimore, MD; Toledo Community CCOP, Toledo, OH
| | - K. Ballman
- Mayo Clinic College of Medicine, Rochester, MN; MD Anderson, Houston, TX; Johns Hopkins University School of Medicine, Baltimore, MD; Toledo Community CCOP, Toledo, OH
| | - B. W. Scheithauer
- Mayo Clinic College of Medicine, Rochester, MN; MD Anderson, Houston, TX; Johns Hopkins University School of Medicine, Baltimore, MD; Toledo Community CCOP, Toledo, OH
| | - P. C. Burger
- Mayo Clinic College of Medicine, Rochester, MN; MD Anderson, Houston, TX; Johns Hopkins University School of Medicine, Baltimore, MD; Toledo Community CCOP, Toledo, OH
| | - C. Giannini
- Mayo Clinic College of Medicine, Rochester, MN; MD Anderson, Houston, TX; Johns Hopkins University School of Medicine, Baltimore, MD; Toledo Community CCOP, Toledo, OH
| | - P. L. Schaefer
- Mayo Clinic College of Medicine, Rochester, MN; MD Anderson, Houston, TX; Johns Hopkins University School of Medicine, Baltimore, MD; Toledo Community CCOP, Toledo, OH
| | - R. B. Jenkins
- Mayo Clinic College of Medicine, Rochester, MN; MD Anderson, Houston, TX; Johns Hopkins University School of Medicine, Baltimore, MD; Toledo Community CCOP, Toledo, OH
| | - C. D. James
- Mayo Clinic College of Medicine, Rochester, MN; MD Anderson, Houston, TX; Johns Hopkins University School of Medicine, Baltimore, MD; Toledo Community CCOP, Toledo, OH
| |
Collapse
|
17
|
Abstract
SUMMARY
Aging is often associated with locomotor deficits. Behavior in aged Blaberus discoidalis cockroaches was analyzed during horizontal walking, climbing, righting and inclined walking. Adult animals showed a decrease in spontaneous locomotion with increasing age. Tarsal abnormalities,termed `tarsus catch', were often present in aged individuals. In `tarsus catch', the prothoracic leg catches on the mesothoracic leg during the swing phase. This deficit causes alterations of the gait, but animals are able to regain a tripod gait after the perturbation. The tibio-tarsal joint angle in individuals with `tarsus catch' was significantly less than in intact animals. Structural defects were consistently associated with `tarsus catch'. The tracheal tubes in the tarsus and around the tibio-tarsal joint were often discolored and the tarsal pads were hardened in aged cockroaches. All aged individuals were able to climb. However, prior to climbing, some animals with`tarsus catch' failed to show postural changes that are normally seen in young animals. Aged individuals can right as rapidly as 1-week-old adults. However,animals with `tarsus catch' take longer to right than aged intact individuals. Old cockroaches have difficulty climbing an incline of 45°, and leg slipping is extensive. Slipping may be caused by tarsal degeneration, but animals that are unsuccessful in inclined walking often show uncoordinated gaits during the attempt. Escape behavior was examined in aged American cockroaches (Periplaneta americana). They do not show normal escape. However, after decapitation, escape movements return, suggesting that degeneration in head ganglia may actually interfere with escape. These findings provide evidence for age-related changes both in the periphery and in the central nervous system of cockroaches and stress the importance of multi-level approaches to the study of locomotion.
Collapse
Affiliation(s)
- A L Ridgel
- Department of Biology, Case Western Reserve University, Cleveland, OH 44106, USA.
| | | | | |
Collapse
|
18
|
Abstract
The escape behavior of the cockroach is a ballistic behavior with well characterized kinematics. The circuitry known to control the behavior lies in the thoracic ganglia, abdominal ganglia, and abdominal nerve cord. Some evidence suggests inputs may occur from the brain or suboesophageal ganglion. We tested this notion by decapitating cockroaches, removing all descending inputs, and evoking escape responses. The decapitated cockroaches exhibited directionally appropriate escape turns. However, there was a front-to-back gradient of change: the front legs moved little if at all, the middle legs moved in the proper direction but with reduced excursion, and the rear legs moved normally. The same pattern was seen when only inputs from the brain were removed, the suboesophageal ganglion remaining intact and connected to the thoracic ganglia. Electromyogram (EMG) analysis showed that the loss of or reduction in excursion was accompanied by a loss of or reduction in fast motor neuron activity. The loss of fast motor neuron activity was also observed in a reduced preparation in which descending neural signals were reversibly blocked via an isotonic sucrose solution superfusing the neck connectives, indicating that the changes seen were not due to trauma. Our data demonstrate that while the thoracic circuitry is sufficient to produce directional escape, lesion or blockage of the connective affects the excitability of components of the escape circuitry. Because of the rapidity of the escape response, such effects are likely due to the elimination of tonic descending inputs.
Collapse
Affiliation(s)
- P L Schaefer
- Department of Biology, Case Western Reserve University, Cleveland, Ohio 44106-7080, USA
| | | |
Collapse
|
19
|
Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001; 93:1246-56. [PMID: 11504770 DOI: 10.1093/jnci/93.16.1246] [Citation(s) in RCA: 418] [Impact Index Per Article: 18.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Survival of patients with anaplastic astrocytoma is highly variable. Prognostic markers would thus be useful to identify clinical subsets of such patients. Because specific genetic alterations have been associated with glioblastoma, we investigated whether similar genetic alterations could be detected in patients with anaplastic astrocytoma and used to identify those with particularly aggressive disease. METHODS Tissue specimens were collected from 174 patients enrolled in Mayo Clinic Cancer Center and North Central Cancer Treatment Group clinical trials for newly diagnosed gliomas, including 63 with anaplastic astrocytoma and 111 with glioblastoma multiforme. Alterations of the EGFR, PTEN, and p53 genes and of chromosomes 7 and 10 were examined by fluorescence in situ hybridization, semiquantitative polymerase chain reaction, and DNA sequencing. All statistical tests were two-sided. RESULTS Mutation of PTEN, amplification of EGFR, and loss of the q arm of chromosome 10 were statistically significantly less common in anaplastic astrocytoma than in glioblastoma multiforme (P =.033, P =.001, and P<.001, respectively), and mutation of p53 was statistically significantly more common (P<.001). Univariate survival analyses of patients with anaplastic astrocytoma identified PTEN (P =.002) and p53 (P =.012) mutations as statistically significantly associated with reduced and prolonged survival, respectively. Multivariate Cox analysis of patients with anaplastic astrocytoma showed that PTEN mutation remained a powerful prognostic factor after adjusting for patient age, on-study performance score, and extent of tumor resection (hazard ratio = 4.34; 95% confidence interval = 1.82 to 10.34). Multivariate classification and regression-tree analysis of all 174 patients identified EGFR amplification as an independent predictor of prolonged survival in patients with glioblastoma multiforme who were older than 60 years of age. CONCLUSION PTEN mutation and EGFR amplification are important prognostic factors in patients with anaplastic astrocytoma and in older patients with glioblastoma multiforme, respectively.
Collapse
Affiliation(s)
- J S Smith
- Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Tefferi A, Li CY, Reeder CB, Geyer SM, Allmer C, Levitt R, Michalak JC, Addo F, Krook JE, Witzig TE, Schaefer PL, Mailliard JA. A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia. Leukemia 2001; 15:1171-5. [PMID: 11480558 DOI: 10.1038/sj.leu.2402172] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
In an earlier study of previously untreated patients with chronic lymphocytic leukemia (CLL), we used a concomitant combination of chlorambucil and 2-chlorodeoxyadenosine and reported overall (OR) and complete (CR) remission rates of 80% and 20%, respectively. After a median follow-up of 5 years, more than 80% of the responders have had a relapse. In the current phase II study of 27 previously untreated patients with CLL, we used a sequential combination of six cycles of intravenous cyclophosphamide (1 g/m2) plus oral prednisone (100 mg/m2 per day for 5 days) followed by two to six cycles of 2-chlorodeoxyadenosine (5 mg/m2 per day for 5 days). The OR and CR rates were 96% and 33%, respectively. After a median follow-up of 29 months, 35% of the responders have had a relapse. Progression-free survival was significantly better in CR patients than in those with partial remission. However, minimal residual disease was phenotypically detected in four of the nine CR patients. Despite the fact that the current OR and CR rates are superior to those seen in a historical cohort treated with a concomitant schedule, a longer follow-up period is needed to assess the durability of these remissions, and a controlled trial is necessary to estimate the impact on overall survival and toxicity.
Collapse
Affiliation(s)
- A Tefferi
- Mayo Clinic, Rochester, MN 55905, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Sloan JA, Loprinzi CL, Laurine JA, Novotny PJ, Vargas-Chanes D, Krook JE, O'Connell MJ, Kugler JW, Tirona MT, Kardinal CG, Wiesenfeld M, Tschetter LK, Hatfield AK, Schaefer PL. A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index. J Clin Oncol 2001; 19:3539-46. [PMID: 11481361 DOI: 10.1200/jco.2001.19.15.3539] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE This article summarizes the third step of a research program to identify variables that supplement the predictive power of the the Eastern Cooperative Oncology Group (ECOG) performance status (PS) for survival. The objective was to produce a simple, practical, stratification factor for phase III oncology clinical trials involving patients with advanced malignant disease. PATIENTS AND METHODS A questionnaire was administered to 729 patients with metastatic colorectal or lung cancers. Patients provided a Karnofsky index and appetite rating while physicians provided a survival estimate and the ECOG-PS. Scores for each item were categorized as having a positive, neutral, or negative indication for survival. A patient was classified as having a relatively good prognosis if three or more of the four items showed a positive indication, a bad prognosis if three or more items were negative, and an uncertain prognosis otherwise (Good/Bad/Uncertain [GBU] index). RESULTS The GBU index improved on the prognostic power of a Cox model quartile index and PS alone and increased the accuracy of survival classification estimates by 5% to 10% more than ECOG-PS alone. For patients with PS of 0 or 1, significant survival patterns exist between GBU groups (P=.002 and.0001, respectively). CONCLUSION The GBU index may be recommended as a supplementary stratification factor for certain future phase III trials in metastatic lung or colorectal cancer where patient heterogeneity is a particular concern. The GBU represents a relatively modest increase to the cost and patient burden of a clinical trial given the additional control that is achieved over the potentially confounding concomitant to the treatment variable.
Collapse
Affiliation(s)
- J A Sloan
- Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Sparano JA, O'Neill A, Schaefer PL, Falkson CI, Wood WC. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J Clin Oncol 2000; 18:2369-77. [PMID: 10856096 DOI: 10.1200/jco.2000.18.12.2369] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE The purpose of this multi-institutional phase II trial was to evaluate the efficacy and toxicity of doxorubicin and docetaxel plus granulocyte colony-stimulating factor (G-CSF) in patients with metastatic breast cancer. The primary objective was to determine whether the combination produced a response rate of at least 50%. PATIENTS AND METHODS Fifty-four patients with metastatic breast cancer received doxorubicin (60 mg/m(2) by intravenous [IV] injection) followed 1 hour later by docetaxel (60 mg/m(2) by IV infusion over 1 hour) every 3 weeks for up to eight cycles. All patients also received G-CSF. RESULTS Objective response occurred in 29 (57%) of 51 eligible patients (95% confidence interval [CI], 42% to 70%), including three patients who had a complete response (6%; 95% CI, 1% to 16%). The median response duration was 7 months (95% CI, 6.0 to 15.0 months), median time to treatment failure was 7. 6 months (95% CI, 6.2 to 9.9 months), and the median survival was 27. 5 months (95% CI, 21.5 months to upper limit not reached). The median cumulative doxorubicin dose was 395 mg/m(2) (range, 60 to 480 mg/m(2)). Fifteen patients (28%) were documented to have a decrease in the left ventricular ejection fraction below normal, and three patients (6%; 95% CI, 1% to 15%) developed congestive heart failure. CONCLUSION Using criteria that we had defined a priori, the doxorubicin-docetaxel regimen as used in this study was sufficiently active and tolerable to justify a phase III comparison with doxorubicin-cyclophosphamide in early-stage breast cancer.
Collapse
Affiliation(s)
- J A Sparano
- Albert Einstein Comprehensive Cancer Center, Montefiore Medical Center, Bronx, NY 10461-2373, USA
| | | | | | | | | |
Collapse
|
23
|
Weitz JJ, Marschke RF, Sloan JA, Grill JP, Jett JR, Knost JA, Hatfield AK, Zenk DW, Bate WW, Schaefer PL. A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer. Lung Cancer 2000; 28:157-62. [PMID: 10717333 DOI: 10.1016/s0169-5002(99)00128-2] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
We conducted a randomized phase II trial of two different schedules of topotecan in patients with advanced-stage non small lung cancer (NSCLC) without prior cytotoxic chemotherapy. All patients had histologic or cytologic confirmation of stage IV (M1) or III-B NSCLC. Patients were stratified by performance status, stage and weight loss. Patients were randomized to receive topotecan at intravenous doses of 1.5 mg/m(2)/day over 30 min for 5 days every 3 weeks (Arm A) or 1.3 mg/m(2)grade 3 in both arms included leukopenia, thrombocytopenia, malaise, constipation, diarrhea, lethargy, pulmonary, vomiting, infection and myalgia. Severe (> or = grade 3) thrombocytopenia occurred in 15.8% of Arm A patients and 37.8% of Arm B patients and this difference was statistically significant (P=0.03). The median times to progression are 101 and 63 days (P=0. 75) and the median survival times are 257 and 179 days (P=0.83) for Arms A and B, respectively. These differences in time to progression and overall survival are not statistically significant. Topotecan has limited, single agent activity in advanced NSCLC when given as 1. 5 mg/m(2)/day over 30 min for 5 days every 3 weeks. We do not intend to pursue further investigations with topotecan in patients with NSCLC.
Collapse
Affiliation(s)
- J J Weitz
- CentraCare Clinic, St. Cloud, 56301, MN, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Perry A, Jenkins RB, O'Fallon JR, Schaefer PL, Kimmel DW, Mahoney MR, Scheithauer BW, Smith SM, Hill EM, Sebo TJ, Levitt R, Krook J, Tschetter LK, Morton RF, Buckner JC. Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors. An analysis of DNA content (ploidy), cellular proliferation, and p53 expression. Cancer 1999. [PMID: 10440696 DOI: 10.1002/(sici)1097-0142(19990815)86:4<672::aid-cncr17>3.0.co;2-g] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
BACKGROUND The biologic behavior of anaplastic (World Health Organization Grade III) astrocytomas and oligoastrocytomas is highly variable, ranging from rapid progression to prolonged survival. It is difficult to predict the outcome of an individual patient based on morphology alone. METHODS To determine the prognostic value of commonly used clinicopathologic markers, we reviewed our experience with 85 similarly treated patients enrolled in 3 North Central Cancer Treatment Group high grade glioma protocols. The pathology was comprised exclusively of primary anaplastic astrocytic tumors (66 astrocytomas and 19 oligoastrocytomas). Variables examined included patient age, morphologic type, preoperative performance score, extent of surgery, solitary versus multiple mitoses, DNA flow cytometric and image morphometric parameters, and expression of proliferating cell nuclear antigen, MIB-1, and p53 expression. RESULTS The study was comprised of 48 men and 37 women ranging in age from 14-79 years (median age, 47 years). Overall survival ranged from <1 month to >12 years (median, 21.6 months). Statistical analyses revealed that age accounted for the majority of this extensive variability in survival. The median survival times were 65. 5 months, 22.1 months, and 4.4 months, respectively, for the groups <40 years, 40-59 years, and >/=60 years, respectively (P < 0.0001). On univariate analyses, aneuploidy by flow cytometry and a low performance score also predicted a better survival (P values of 0.04 and 0.009, respectively). Statistical trends predicting a better survival were observed for patients with a solitary mitosis and p53 immunopositivity. However, only patient age remained significant in multivariate models. CONCLUSIONS In a small but relatively uniformly treated cohort of patients with anaplastic astrocytomas and oligoastrocytomas, patient age was associated strongly and inversely with overall survival. Once patient age was taken into account, the clinical and pathologic markers tested appeared to be of limited prognostic value.
Collapse
Affiliation(s)
- A Perry
- Washington University School of Medicine, St. Louis, Missouri, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Perry A, Jenkins RB, O'Fallon JR, Schaefer PL, Kimmel DW, Mahoney MR, Scheithauer BW, Smith SM, Hill EM, Sebo TJ, Levitt R, Krook J, Tschetter LK, Morton RF, Buckner JC. Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors. An analysis of DNA content (ploidy), cellular proliferation, and p53 expression. Cancer 1999; 86:672-83. [PMID: 10440696 DOI: 10.1002/(sici)1097-0142(19990815)86:4<672::aid-cncr17>3.0.co;2-g] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND The biologic behavior of anaplastic (World Health Organization Grade III) astrocytomas and oligoastrocytomas is highly variable, ranging from rapid progression to prolonged survival. It is difficult to predict the outcome of an individual patient based on morphology alone. METHODS To determine the prognostic value of commonly used clinicopathologic markers, we reviewed our experience with 85 similarly treated patients enrolled in 3 North Central Cancer Treatment Group high grade glioma protocols. The pathology was comprised exclusively of primary anaplastic astrocytic tumors (66 astrocytomas and 19 oligoastrocytomas). Variables examined included patient age, morphologic type, preoperative performance score, extent of surgery, solitary versus multiple mitoses, DNA flow cytometric and image morphometric parameters, and expression of proliferating cell nuclear antigen, MIB-1, and p53 expression. RESULTS The study was comprised of 48 men and 37 women ranging in age from 14-79 years (median age, 47 years). Overall survival ranged from <1 month to >12 years (median, 21.6 months). Statistical analyses revealed that age accounted for the majority of this extensive variability in survival. The median survival times were 65. 5 months, 22.1 months, and 4.4 months, respectively, for the groups <40 years, 40-59 years, and >/=60 years, respectively (P < 0.0001). On univariate analyses, aneuploidy by flow cytometry and a low performance score also predicted a better survival (P values of 0.04 and 0.009, respectively). Statistical trends predicting a better survival were observed for patients with a solitary mitosis and p53 immunopositivity. However, only patient age remained significant in multivariate models. CONCLUSIONS In a small but relatively uniformly treated cohort of patients with anaplastic astrocytomas and oligoastrocytomas, patient age was associated strongly and inversely with overall survival. Once patient age was taken into account, the clinical and pathologic markers tested appeared to be of limited prognostic value.
Collapse
Affiliation(s)
- A Perry
- Washington University School of Medicine, St. Louis, Missouri, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Creagan ET, Veeder MH, Suman VJ, Burch PA, Maples WJ, Schaefer PL, Pfeifle DM, Dalton RJ, Hatfield AK, Poon MA. A phase II study of high-dose cimetidine and the combination 5-fluorouracil, interferon alpha-2A, and leucovorin in advanced renal cell adenocarcinoma. Am J Clin Oncol 1998; 21:475-8. [PMID: 9781603 DOI: 10.1097/00000421-199810000-00011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Cimetidine is an H2-receptor antagonist used in the management of peptic ulcer disease and other hypersecretory gastrointestinal disorders. This agent has intriguing immunomodulatory characteristics. A phase II trial of cimetidine in 19 patients with advanced malignant melanoma yielded an objective response rate of 16%. Having demonstrated that cimetidine is active in malignant melanoma, the authors conducted a phase II trial of cimetidine, 800 mg twice daily by mouth, in patients with advanced renal cell cancer. Among the 31 eligible patients, only one (3.2%) achieved a regression. It was a partial regression lasting 93 days. Median time to treatment failure was 83 days. The combination of interferon alpha-2A (IFL-RA) and 5-fluorouracil (5-FU) has been shown to be synergistic against experimental cell lines in vitro. Citrovorum factor (CF) added to 5-FU has been shown to improve objective tumor response compared with single-agent 5-FU in patients with advanced colorectal cancer. Fluorinated pyrimidines have shown some activity against renal cell cancer. We conducted a phase II trial of the combination of CF at 20 mg/m2 intravenous push followed by 5-FU at 325 mg/m2 intravenously daily for 5 days every week with interferon alpha-2A 5 x 10(6) units/m2 subcutaneously on days 1, 3, 5 in patients with advanced renal cell cancer. Among the 31 eligible patients, only two (6.5%) achieved a regression. Both were partial regressions. Median time to treatment failure was 84 days. Neither regimen is recommended for further testing in patients with advanced renal cell adenocarcinoma.
Collapse
Affiliation(s)
- E T Creagan
- Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Galanis E, Buckner JC, Burch PA, Schaefer PL, Dinapoli RP, Novotny PJ, Scheithauer BW, Rowland KM, Vukov AM, Mailliard JA, Morton RF. Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. J Clin Oncol 1998; 16:2953-8. [PMID: 9738563 DOI: 10.1200/jco.1998.16.9.2953] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Previous investigators have reported responses in 52% of patients treated with mechlorethamine (nitrogen mustard), vincristine, and procarbazine (MOP) for recurrent glioma. To confirm these promising results, we conducted a phase II prospective study. PATIENTS AND METHODS Sixty-three patients with histologic confirmation of recurrent glioma were treated with the MOP regimen. Patients with or without prior chemotherapy received nitrogen mustard 3 mg/m2 or 6 mg/m2, respectively, intravenously on days 1 and 8 plus vincristine 2 mg/m2 intravenously on days 1 and 8, and procarbazine 100 mg/m2 orally on days 1 to 14. Cycles were repeated every 28 days. RESULTS Of 61 patients assessable for response, eight responded (13%), with one complete response (CR). Responses were as follows: low-grade gliomas, 19%; anaplastic astrocytomas, 11%; anaplastic oligodendrogliomas or oligoastrocytomas, 25%; and glioblastomas, 4.3%. The most common toxicity was myelosuppression with leukocyte nadirs less than 1,000/microL in 23% and platelet nadirs less than 25,000/microL in 13% of patients. Two patients died of infection in the setting of neutropenia. Nonhematologic toxicity included neurosensory changes in 21% of patients (severe in 3%) and severe dermatologic reactions in 8%. In multivariate analysis, Eastern Cooperative Oncology group (ECOG) performance status (PS) was the best predictor for response to chemotherapy (P=.01) and time to progression (P=.008), while PS and grade were the most important predictors of survival (P=.002 and .05, respectively). CONCLUSION This study did not confirm the high response rate previously reported in recurrent gliomas. Patients with recurrent anaplastic oligodendrogliomas or oligoastrocytomas and recurrent low-grade gliomas had the highest response rates (25% and 19%, respectively). In multivariate analysis, ECOG PS was the best predictor of response, while PS and tumor grade were the most important predictors of survival.
Collapse
Affiliation(s)
- E Galanis
- Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Taylor BV, Buckner JC, Cascino TL, O'Fallon JR, Schaefer PL, Dinapoli RP, Schomberg P. Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma. J Clin Oncol 1998; 16:2195-201. [PMID: 9626221 DOI: 10.1200/jco.1998.16.6.2195] [Citation(s) in RCA: 75] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE The effect of radiotherapy on the long-term cognitive performance of patients treated for intracranial neoplasm is a major concern to clinicians and patients, particularly as long-term survival or cure is possible for a small minority of patients. To assess the effects of cranial radiotherapy and chemotherapy on the cognitive performance of high-grade glioma patients, we analyzed cognitive performance data collected in a series of prospective clinical trials. METHODS We studied 701 high-grade brain tumor patients entered onto two consecutive North Central Cancer Treatment Group (NCCTG) randomized treatment trials designed to compare radiotherapy and carmustine (BCNU) versus radiotherapy and 1-(2-chloroethyl)-3(2,6 dioxo-l-piperidyl)-1-nitrosource a (PCNU) (first trial) and radiotherapy and BCNU and interferon alfa (IFN) versus radiotherapy and BCNU (second trial). Folstein Mini-Mental Status Exam (MMSE) score and Eastern Cooperative Oncology Group (ECOG) performance score (PS) recorded at baseline and 6, 12, 18, and 24 months were analyzed to assess cognitive and physical function over time. Patients who did not demonstrate tumor progression within 60 days of the assessment time were considered nonprogressors at that evaluation. A loss of greater than 3 points on the MMSE was considered significant deterioration. RESULTS The number of patients who experienced a greater than 3-point decrease in MMSE from baseline was 13 of 119 nonprogressors (10.9%; 95% confidence interval [CI], 6.3% to 18.9%) at 6 months, three of 54 nonprogressors (5.5%; 95% CI, 0.5% to 12.8%) at 12 months, three of 30 nonprogressors (10%; 95% CI, 2.1% to 26.5%) at 18 months, and four of 22 nonprogressors (18.2%; 95% CI, 5.2% to 40.3%) at 24 months. The CIs at all times overlapped, which indicates no statistically significant increase in the percentage of patients who experienced a significant decrease in their MMSE score. Patients who demonstrated a significant decrease in their MMSE score were significantly older than those who did not (P = .0017) at 6 months and remained so throughout follow-up; moreover, they had a significantly shorter time to progression and death. ECOG PS was strongly negatively correlated with MMSE score throughout the study, and MMSE score at all time intervals was correlated with baseline PS. CONCLUSION In this population of glioma patients who received radiotherapy, there is no clear trend to cognitive worsening. Factors such as older age, poorer PS, and subclinical tumor progression may be more significant factors in those patients who did demonstrate a significant cognitive decline.
Collapse
|
29
|
Goldberg RM, Hatfield AK, Kahn M, Sargent DJ, Knost JA, O'Connell MJ, Krook JE, Maillard JA, Wiesenfeld M, Schaefer PL, Tirona MT, Moertel CG. Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. J Clin Oncol 1997; 15:3320-9. [PMID: 9363861 DOI: 10.1200/jco.1997.15.11.3320] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
PURPOSE A three-arm randomized phase III trial in advanced colorectal cancer patients was designed to test whether substitution of an equivalent dose of (1) l-leucovorin or (2) oral leucovorin would more effectively potentiate fluorouracil (5-FU) than standard intravenous (I.V.) (d,l)-leucovorin. PATIENTS AND METHODS A total of 926 chemotherapy-naive patients participated. Patients received one of three treatments: (A) intensive-course 5-FU plus l-leucovorin with I.V. leucovorin (Immunex Corp, Seattle, WA) at 100 mg/m2 and I.V. 5-FU at 370 mg/m2; (B) intensive-course 5-FU plus oral (d,l)-leucovorin with oral leucovarin at 125 mg/m2 on hours 0, 1, 2, and 3 (total dose, 500 mg/m2) followed by 5-FU 370 mg/m2 on hour 4; or (C) intensive-course 5-FU plus I.V. (d,l)-leucovorin with I.V. leucovorin 200 mg/m2 and 5-FU 370 mg/m2. Drugs were administered daily for 5 consecutive days. Courses were repeated at 4 and 8 weeks, and every 5 weeks thereafter. Dosage was reduced for neutropenia, thrombocytopenia, diarrhea, stomatitis, and dermatitis. RESULTS Of 926 eligible patients, 756 have died. The overall response rate for patients with measurable disease was 32% (165 of 514). There were no differences between regimens in response rates (arm A, 28% [47 of 140]; arm B, 34% [60 of 174]; and arm C, 34% [58 of 170]) or in survival. There have been nine possible chemotherapy-related fatalities. Grade III to IV toxic effects did not differ appreciably by arm and included stomatitis (12% to 14%), diarrhea (15% to 19%), nausea (7% to 9%), and vomiting (6% to 8%). CONCLUSION There was no difference in response, survival, or toxicity between these three different leucovorin formulations combined with 5-FU.
Collapse
Affiliation(s)
- R M Goldberg
- Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Ingle JN, Kardinal CG, Suman VJ, Veeder MH, Schaefer PL, Kirschling RJ, Mailliard JA. Mitoxantrone dose augmentation utilizing filgrastim support in combination with fixed-dose 5-fluorouracil and leucovorin in women with metastatic breast cancer. Breast Cancer Res Treat 1997; 43:193-200. [PMID: 9150898 DOI: 10.1023/a:1005749115033] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Based on reports of substantial antitumor efficacy of the combination of mitoxantrone (DHAD), 5-fluorouracil (FU) and leucovorin (LV), a clinical trial was performed to attempt augmentation of the dose of DHAD with filgrastim support. The doses and schedules, all intravenous, were DHAD (total dose divided over days 1 and 2), level I, 16 mg/m2; II, 20 mg/m2; III, 24 mg/m2; IV, 32 mg/m2; and LV, 300 mg, followed by FU, 350 mg/m2, on days 1-3. Filgrastim was given at 5 micrograms/kg/day subcutaneously on days 4-13. The planned cycle length was 21 days. Three or 4 patients were to be entered at each dose level and the maximum tolerated dose (MTD) was defined as the dose immediately below that which resulted in 2 patients with dose-limiting toxicity (DLT) in cycle 1. Once an apparent MTD was identified, an additional 6 patients were to be entered. Twenty patients (pts) were entered: level I: 3 pts; II: 3 pts; III: 10 pts: IV: 4 pts. The major toxicity was found to be cumulative thrombocytopenia with platelet counts < or = 20,000/microL occurring after cycle 1 at all levels beyond level I and five pts (25%) were removed from treatment solely because of platelet toxicity. Additional serious toxicities included grade 4 stomatitis in one patient (level IV) and cardiac toxicity in 2 patients with prior doxorubicin exposure. Ten pts had measurable and 8 had evaluable disease, and in 17 pts assessed, 5 (29%) achieved an objective response. The response rates in this study are lower than reported in the literature for the combination of DHAD, 5FU, LV and this may be related to the fact that only 40% of the patients were removed from protocol treatment because of disease progression. On the basis of limited DHAD-dose augmentation, toxicities observed, and modest response rate, the filgrastim-supported DHAD, 5FU, LV regimen as utilized in this study cannot be recommended for further development for treatment of women with metastatic breast cancer.
Collapse
Affiliation(s)
- J N Ingle
- Mayo Clinic, Rochester, MN 55905, USA
| | | | | | | | | | | | | |
Collapse
|
31
|
Loprinzi CL, Ghosh C, Camoriano J, Sloan J, Steen PD, Michalak JC, Schaefer PL, Novotny PJ, Gerstner JB, White DF, Hatfield AK, Quella SK. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. J Clin Oncol 1997; 15:1235-8. [PMID: 9060567 DOI: 10.1200/jco.1997.15.3.1235] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
PURPOSE Stomatitis is a major dose-limiting toxicity of bolus fluorouracil (5FU)-based chemotherapy regimens, despite the use of oral cryotherapy. Pursuant to preliminary data that suggested a sucralfate oral solution could alleviate chemotherapy-induced oral mucositis, we developed a prospective trial to test this contention. PATIENTS AND METHODS A phase III, double-blind, placebo-controlled clinical trial was designed. Patients were entered onto the study at the time of the first cycle of 5FU-based chemotherapy. All patients received oral cryotherapy for 30 minutes with each dose of 5FU. In addition, each patient was randomized to receive either a sucralfate solution or a placebo solution to be used if they developed mouth tenderness or mouth sores. The study solution was to be used four times daily for 7 days starting on the first day of mouth tenderness or mouth sores. Stomatitis scores were determined by health care providers and by patients themselves. RESULTS There was a total of 131 assessable patients entered onto this trial, 50 of whom developed mucositis and used the study medication (27 sucralfate and 23 placebo). There was no suggestion of any difference in stomatitis severity or duration on either protocol arm. CONCLUSION The resultant data from this clinical trial did not support the prestudy hypothesis that sucralfate would be beneficial for the treatment of 5FU-induced stomatitis.
Collapse
Affiliation(s)
- C L Loprinzi
- Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Rowland KM, Loprinzi CL, Shaw EG, Maksymiuk AW, Kuross SA, Jung SH, Kugler JW, Tschetter LK, Ghosh C, Schaefer PL, Owen D, Washburn JH, Webb TA, Mailliard JA, Jett JR. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 1996; 14:135-41. [PMID: 8558188 DOI: 10.1200/jco.1996.14.1.135] [Citation(s) in RCA: 96] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
PURPOSE Megestrol acetate has been reported to improve appetite and quality of life and to decrease nausea and vomiting in patients with cancer anorexia/cachexia. The present trial was formulated to evaluate the impact of megestrol acetate on quality of life, toxicity, response, and survival in individuals with extensive-stage small-cell lung cancer who received concomitant chemotherapy. PATIENTS AND METHODS Patients were randomized to receive megestrol acetate 800 mg/d orally or placebo. In addition, all patients were scheduled to receive a maximum of four cycles of cisplatin and etoposide chemotherapy. Quality of life was self-assessed at entry onto study, with every cycle of chemotherapy, and 4 months thereafter with a linear visual analog scale. Toxicity was evaluated by patient questionnaire and investigator reports. RESULTS A total of 243 eligible patients were randomized. Those who received megestrol acetate had increased nonfluid weight gain (P = .004) and significantly less nausea (P = .0002) and vomiting (P = .02). Significant thromboembolic phenomena occurred more often in patients who received megestrol acetate versus placebo (9% v 2%, P = .01). Patients who received megestrol acetate had more edema (30% v 20%, P = .002), an inferior response rate to chemotherapy (68% v 80%, P = .03), and a trend for inferior survival duration (median, 8.2 v 10.0 months, P = .49). These findings may have been influenced by a poorer quality of life of the megestrol acetate group at study initiation. There were no significant changes in quality of life scores over time between either of the study arms. CONCLUSION Megestrol acetate cannot be routinely recommended for all patients with small-cell lung cancer at the time of chemotherapy initiation. Rather, its therapeutic ratio may be more favorable for patients with problematic cancer anorexia/cachexia.
Collapse
|
33
|
Fukuyama K, Matsuzawa K, Hubbard SL, Dirks P, Rulka JT, Maisuzawa K, Hubbard SL, Rutka JT, Del Maestro RF, Vaithilingam IS, McDonald W, Weiss JB, Mikkelsen T, Kohn E, Nclson K, Rosenblum ML, Guha A, Shamah S, Stiles C, Dooley NP, Baltuch GH, Roslworowski M, Villemure JG, Yong VW, Baltuch G, Rostworowski M, Couldwell WT, Hinton DR, Weiss MH, Law R, Couldwell WT, Hinton DR, Law R, Weiss MH, Piepmeier JM, Pedersen PE, Greer CA, Dirks PB, Hubbard SL, Taghian A, Budach W, Freeman J, Gioioso D, Suit HD, Turner J, Barron G, Zia P, Wong CS, Van Dyk J, Milosevic M, Laperriere NJ, Myles ST, Lauryssen C, Shaw EG, Scheithauer BW, Suman V, Katzmann J, Preul M, Shenouda G, Langleben A, Arnold D, Watling C, van Meyel D, Ramsay D, Cairncross G, Bahary JP, Wainer I, Pollak M, Leyland-Jones B, Tsatoumas A, Choi A, Rosenfeld SS, Gillespie GY, Gladson CL, Drake JM, Hoffman HJ, Humphreys RP, Holowka S, Fullon DS, Urtasun RC, Hamilton MG, Beals S, Joganic E, Spetzler R, Buckner JC, Schaefer PL, Dinapolit RP, O'Fallon JR, Burch PA, Chandler CL, Hopkins K, Coakham HB, Bullimore J, Kemshead JT, Bernstein M, Laperriere N, MeKenzie S, Glen J, Lee D, Macdonald D, Sneed PK, Gulin PG, Larson DA, McDermott MW, Prados MD, Wara WM, Weaver KA, Gaspar L, Zamorano L, Garcia L, Shamsa F, Warmelink C, Yakar D, Espinosa JA, Souhami L, Caron JL, Olivier A, Podgorsak EB, Lindquist C, Loeffler JS, Lunsford LD, Newton HB, Kotur MD, Papp AC, Prior TW, Roosen N, Chopra R, Windham J, Parliament M, Franko A, Mielke B, Feindel W, Tampieri D, Mechtler LL, Wilheim-Leitch S, Shin K, Kinkel WR, Hammoud MA, Sawaya R, Shi W, Thall PP, Leeds N, Patel M, Truax B, Kinkel P, Cheng TM, O'Ncill BP, Piepgras DG, Frost PJ, Simpson WJS, Payne DG, Pintilie M, Ramsay DA, Bonnin J, Macdonald DR, Assis L, Villemurel JG, Choi S, Leblancl R, Olivieri A, Bertrandl G, Hazel J, Grand W, Plunkett R, Munschauer F, Ostrow P, Mcchtler L, Meckling S, Dold O, Forsyth P, Brasher P, Hagen N, Hudson LP, Cooke AL, Muller PJ, Tucker W, Moulton R, Cusimano M, Bilbao J, Pahapill PA, Sibala C, West C, Fisher B, Pexman W, Taylor J, Lee T, McKenzie SW, Zengmin T, Zonghui L, Kirby S, Fisher BJ, Stewart DJ, Roa W, McClean B, Buckney S, Halls S, Richardson S, Wilson BC, Whitton AC, Borr RD, Rhydderch H, Case T, Feeny D, Furlong W, Torrance GW. Abstracts of the 6th Canadian Neuro-Oncology Meeting May 18–21, 1994 Lake Louise, Alberta. J Neurooncol 1994. [DOI: 10.1007/bf01306460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
34
|
Schaefer PL, Kondagunta GV, Ritzmann RE. Motion analysis of escape movements evoked by tactile stimulation in the cockroach Periplaneta americana. J Exp Biol 1994; 190:287-94. [PMID: 7964395 DOI: 10.1242/jeb.190.1.287] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- P L Schaefer
- Department of Biology, Case Western Reserve University, Cleveland, OH 44106
| | | | | |
Collapse
|
35
|
Buroker TR, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailliard JA, Schaefer PL, Levitt R, Kardinal CG, Gesme DH. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12:14-20. [PMID: 7677801 DOI: 10.1200/jco.1994.12.1.14] [Citation(s) in RCA: 216] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
PURPOSE To compare two commonly used schedules of fluorouracil (5FU) and leucovorin in the treatment of patients with advanced metastatic colorectal cancer. Each of these dosage administration schedules has been demonstrated to be superior to single-agent bolus 5FU in previous controlled trials. PATIENTS AND METHODS Three hundred seventy-two ambulatory patients with metastatic colorectal cancer were stratified according to performance status, and presence and location of any measurable indicator lesion(s). They were then randomized to receive chemotherapy with one of the following regimens: (1) intensive-course 5FU plus low-dose leucovorin (5FU 425 mg/m2 plus leucovorin 20 mg/m2 intravenous [IV] push daily for 5 days with courses repeated at 4- to 5-week intervals); (2) weekly 5FU plus high-dose leucovorin (5FU 600 mg/m2 IV push plus leucovorin 500 mg/m2 as a 2-hour infusion weekly for 6 weeks with courses repeated every 8 weeks). RESULTS Three hundred sixty-two of 372 patients randomized (97.3%) were eligible and included in the analysis. Three hundred forty-six patients (95.6%) have died. There were no significant differences in therapeutic efficacy between the two 5FU/leucovorin regimens tested with respect to the following parameters: objective tumor response (35% v 31%), survival (median, 9.3 v 10.7 months), and palliative effects (as assessed by relief of symptoms, improved performance status, and weight gain). There were significant (P < .05) differences in toxicity, with more leukopenia and stomatitis seen with the intensive-course regimen, and more diarrhea and requirement for hospitalization to manage toxicity with the weekly regimen. Financial cost was also higher with the weekly regimen. CONCLUSION Intensive-course 5FU plus low-dose leucovorin appears to have a superior therapeutic index compared with weekly 5FU plus high-dose leucovorin using the dosage administration schedules applied in this study based on similar therapeutic effectiveness, but lower financial cost, and less need for hospitalization to manage chemotherapy toxicity.
Collapse
Affiliation(s)
- T R Buroker
- Iowa Oncology Research Association Community Clinical Oncology Program (CCOP), Des Moines
| | | | | | | | | | | | | | | | | | | |
Collapse
|